ID   CSF1R_HUMAN             Reviewed;         972 AA.
AC   P07333; B5A955; D3DQG2; Q6LDW5; Q6LDY4; Q86VW7;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   10-MAY-2017, entry version 199.
DE   RecName: Full=Macrophage colony-stimulating factor 1 receptor;
DE   AltName: Full=CSF-1 receptor;
DE            Short=CSF-1-R;
DE            Short=CSF-1R;
DE            Short=M-CSF-R;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Fms;
DE   AltName: CD_antigen=CD115;
DE   Flags: Precursor;
GN   Name=CSF1R; Synonyms=FMS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2524025;
RA   Hampe A., Shamoon B.M., Gobet M., Sherr C.J., Galibert F.;
RT   "Nucleotide sequence and structural organization of the human FMS
RT   proto-oncogene.";
RL   Oncogene Res. 4:9-17(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2421165; DOI=10.1038/320277a0;
RA   Coussens L., van Beveren C., Smith D., Chen E., Mitchell R.L.,
RA   Isacke C.M., Verma I.M., Ullrich A.;
RT   "Structural alteration of viral homologue of receptor proto-oncogene
RT   fms at carboxyl terminus.";
RL   Nature 320:277-280(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V.,
RA   Hu W.X., Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the
RT   FMS receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=2524648; DOI=10.1128/MCB.9.3.1336;
RA   Visvader J., Verma I.M.;
RT   "Differential transcription of exon 1 of the human c-fms gene in
RT   placental trophoblasts and monocytes.";
RL   Mol. Cell. Biol. 9:1336-1341(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=3525854;
RA   Wheeler E.F., Roussel M.F., Hampe A., Walker M.H., Fried V.A.,
RA   Look A.T., Rettenmier C.W., Sherr C.J.;
RT   "The amino-terminal domain of the v-fms oncogene product includes a
RT   functional signal peptide that directs synthesis of a transforming
RT   glycoprotein in the absence of feline leukemia virus gag sequences.";
RL   J. Virol. 59:224-233(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RC   TISSUE=Placenta;
RA   Flick M.B., Sapi E., Kacinski B.M.;
RT   "Expression of a novel exon in the 5' UTR of human c-fms
RT   transcripts.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 244-295.
RX   PubMed=4028159; DOI=10.1016/0092-8674(85)90099-6;
RA   Nienhuis A.W., Bunn H.F., Turner P.H., Gopal T.V., Nash W.G.,
RA   O'Brien S.J., Sherr C.J.;
RT   "Expression of the human c-fms proto-oncogene in hematopoietic cells
RT   and its deletion in the 5q- syndrome.";
RL   Cell 42:421-428(1985).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 874-972 (ISOFORM 1).
RX   PubMed=3532121; DOI=10.1073/pnas.83.20.7800;
RA   Browning P.J., Bunn H.F., Cline A., Shuman M., Nienhuis A.W.;
RT   "'Replacement' of COOH-terminal truncation of v-fms with c-fms
RT   sequences markedly reduces transformation potential.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7800-7804(1986).
RN   [13]
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=7683918;
RA   Bourette R.P., Mouchiroud G., Ouazana R., Morle F., Godet J.,
RA   Blanchet J.P.;
RT   "Expression of human colony-stimulating factor-1 (CSF-1) receptor in
RT   murine pluripotent hematopoietic NFS-60 cells induces long-term
RT   proliferation in response to CSF-1 without loss of erythroid
RT   differentiation potential.";
RL   Blood 81:2511-2520(1993).
RN   [14]
RP   INTERACTION WITH SRC; FYN AND YES1, AND MUTAGENESIS OF TYR-809.
RX   PubMed=7681396;
RA   Courtneidge S.A., Dhand R., Pilat D., Twamley G.M., Waterfield M.D.,
RA   Roussel M.F.;
RT   "Activation of Src family kinases by colony stimulating factor-1, and
RT   their association with its receptor.";
RL   EMBO J. 12:943-950(1993).
RN   [15]
RP   INDUCTION BY GLUCOCORTICOIDS.
RX   PubMed=7845678;
RA   Sapi E., Flick M.B., Gilmore-Hebert M., Rodov S., Kacinski B.M.;
RT   "Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in
RT   human breast carcinoma cells by glucocorticoids.";
RL   Oncogene 10:529-542(1995).
RN   [16]
RP   MUTAGENESIS OF TYR-708 AND ASP-802.
RX   PubMed=10340379; DOI=10.1038/sj.onc.1202646;
RA   Morley G.M., Uden M., Gullick W.J., Dibb N.J.;
RT   "Cell specific transformation by c-fms activating loop mutations is
RT   attributable to constitutive receptor degradation.";
RL   Oncogene 18:3076-3084(1999).
RN   [17]
RP   FUNCTION IN CELLULAR SIGNALING; PHOSPHORYLATION OF INPP5D AND
RP   ACTIVATION OF AKT1.
RX   PubMed=12882960; DOI=10.1074/jbc.M305021200;
RA   Baran C.P., Tridandapani S., Helgason C.D., Humphries R.K.,
RA   Krystal G., Marsh C.B.;
RT   "The inositol 5'-phosphatase SHIP-1 and the Src kinase Lyn negatively
RT   regulate macrophage colony-stimulating factor-induced Akt activity.";
RL   J. Biol. Chem. 278:38628-38636(2003).
RN   [18]
RP   FUNCTION IN REGULATION OF CELL PROLIFERATION; CELL ADHESION; CELL
RP   SHAPE AND INTEGRITY OF CELL JUNCTIONS, MUTAGENESIS OF LEU-301 AND
RP   TYR-969, AND ROLE IN DISEASE.
RX   PubMed=15117969; DOI=10.1083/jcb.200309102;
RA   Wrobel C.N., Debnath J., Lin E., Beausoleil S., Roussel M.F.,
RA   Brugge J.S.;
RT   "Autocrine CSF-1R activation promotes Src-dependent disruption of
RT   mammary epithelial architecture.";
RL   J. Cell Biol. 165:263-273(2004).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-302 AND ASN-353.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [20]
RP   FUNCTION AS CSF1 RECEPTOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=16648572; DOI=10.1158/1535-7163.MCT-05-0359;
RA   Guo J., Marcotte P.A., McCall J.O., Dai Y., Pease L.J.,
RA   Michaelides M.R., Davidsen S.K., Glaser K.B.;
RT   "Inhibition of phosphorylation of the colony-stimulating factor-1
RT   receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and
RT   other tyrosine kinase inhibitors.";
RL   Mol. Cancer Ther. 5:1007-1013(2006).
RN   [21]
RP   FUNCTION IN CELL PROLIFERATION, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=17121910; DOI=10.1158/1535-7163.MCT-05-0313;
RA   Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M.,
RA   Yoneda T., Isoe T.;
RT   "A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast
RT   differentiation and osteolytic bone destruction in a bone metastasis
RT   model.";
RL   Mol. Cancer Ther. 5:2634-2643(2006).
RN   [22]
RP   FUNCTION IN REGULATION OF CELL PROLIFERATION AND CELL SHAPE, CATALYTIC
RP   ACTIVITY, UBIQUITINATION, ENZYME REGULATION, AND MUTAGENESIS OF
RP   ASP-802.
RX   PubMed=16170366; DOI=10.1038/sj.onc.1209007;
RA   Taylor J.R., Brownlow N., Domin J., Dibb N.J.;
RT   "FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor
RT   imatinib and mutation of Asp-802 to Val confers resistance.";
RL   Oncogene 25:147-151(2006).
RN   [23]
RP   FUNCTION AS IL34 RECEPTOR.
RX   PubMed=18467591; DOI=10.1126/science.1154370;
RA   Lin H., Lee E., Hestir K., Leo C., Huang M., Bosch E., Halenbeck R.,
RA   Wu G., Zhou A., Behrens D., Hollenbaugh D., Linnemann T., Qin M.,
RA   Wong J., Chu K., Doberstein S.K., Williams L.T.;
RT   "Discovery of a cytokine and its receptor by functional screening of
RT   the extracellular proteome.";
RL   Science 320:807-811(2008).
RN   [24]
RP   ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=18814279; DOI=10.1002/ijc.23903;
RA   Hiraga T., Nakamura H.;
RT   "Imatinib mesylate suppresses bone metastases of breast cancer by
RT   inhibiting osteoclasts through the blockade of c-Fms signals.";
RL   Int. J. Cancer 124:215-222(2009).
RN   [25]
RP   ROLE IN DISEASE.
RX   PubMed=19934330; DOI=10.1158/0008-5472.CAN-09-1868;
RA   Patsialou A., Wyckoff J., Wang Y., Goswami S., Stanley E.R.,
RA   Condeelis J.S.;
RT   "Invasion of human breast cancer cells in vivo requires both paracrine
RT   and autocrine loops involving the colony-stimulating factor-1
RT   receptor.";
RL   Cancer Res. 69:9498-9506(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-699 AND SER-713, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=20156689; DOI=10.1016/j.bmc.2010.01.056;
RA   Mashkani B., Griffith R., Ashman L.K.;
RT   "Colony stimulating factor-1 receptor as a target for small molecule
RT   inhibitors.";
RL   Bioorg. Med. Chem. 18:1789-1797(2010).
RN   [28]
RP   FUNCTION AS RECEPTOR FOR IL34 AND CSF1, PHOSPHORYLATION AT TYR-546;
RP   TYR-699; TYR-708; TYR-723 AND TYR-809, AUTOPHOSPHORYLATION, ENZYME
RP   REGULATION, AND INTERACTION WITH IL34 AND CSF1.
RX   PubMed=20489731; DOI=10.1038/cdd.2010.60;
RA   Chihara T., Suzu S., Hassan R., Chutiwitoonchai N., Hiyoshi M.,
RA   Motoyoshi K., Kimura F., Okada S.;
RT   "IL-34 and M-CSF share the receptor Fms but are not identical in
RT   biological activity and signal activation.";
RL   Cell Death Differ. 17:1917-1927(2010).
RN   [29]
RP   FUNCTION IN RELEASE OF PROINFLAMMATORY CHEMOKINES.
RX   PubMed=20829061; DOI=10.1016/j.cyto.2010.08.005;
RA   Eda H., Zhang J., Keith R.H., Michener M., Beidler D.R., Monahan J.B.;
RT   "Macrophage-colony stimulating factor and interleukin-34 induce
RT   chemokines in human whole blood.";
RL   Cytokine 52:215-220(2010).
RN   [30]
RP   FUNCTION AS IL34 AND CSF1 RECEPTOR; ACTIVATION OF MAPK1/ERK2;
RP   MAPK3/ERK1; PHOSPHORYLATION AT TYR-723, AND AUTOPHOSPHORYLATION.
RX   PubMed=20504948; DOI=10.1189/jlb.1209822;
RA   Wei S., Nandi S., Chitu V., Yeung Y.G., Yu W., Huang M.,
RA   Williams L.T., Lin H., Stanley E.R.;
RT   "Functional overlap but differential expression of CSF-1 and IL-34 in
RT   their CSF-1 receptor-mediated regulation of myeloid cells.";
RL   J. Leukoc. Biol. 88:495-505(2010).
RN   [31]
RP   REVIEW ON FUNCTION; SIGNALING PATHWAYS AND PHOSPHORYLATION.
RX   PubMed=15519852; DOI=10.1016/j.tcb.2004.09.016;
RA   Pixley F.J., Stanley E.R.;
RT   "CSF-1 regulation of the wandering macrophage: complexity in action.";
RL   Trends Cell Biol. 14:628-638(2004).
RN   [32]
RP   REVIEW ON FUNCTION IN IMMUNITY AND INFLAMMATION, AND ROLE IN DISEASE.
RX   PubMed=16337366; DOI=10.1016/j.coi.2005.11.006;
RA   Chitu V., Stanley E.R.;
RT   "Colony-stimulating factor-1 in immunity and inflammation.";
RL   Curr. Opin. Immunol. 18:39-48(2006).
RN   [33]
RP   REVIEW ON FUNCTION; SIGNALING PATHWAYS AND PHOSPHORYLATION.
RX   PubMed=18687298; DOI=10.1016/j.intimp.2008.04.016;
RA   Douglass T.G., Driggers L., Zhang J.G., Hoa N., Delgado C.,
RA   Williams C.C., Dan Q., Sanchez R., Jeffes E.W., Wepsic H.T.,
RA   Myers M.P., Koths K., Jadus M.R.;
RT   "Macrophage colony stimulating factor: not just for macrophages
RT   anymore! A gateway into complex biologies.";
RL   Int. Immunopharmacol. 8:1354-1376(2008).
RN   [34]
RP   REVIEW.
RX   PubMed=19132917; DOI=10.1146/annurev.immunol.021908.132557;
RA   Auffray C., Sieweke M.H., Geissmann F.;
RT   "Blood monocytes: development, heterogeneity, and relationship with
RT   dendritic cells.";
RL   Annu. Rev. Immunol. 27:669-692(2009).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 538-922 IN COMPLEXES WITH
RP   ARYLAMIDE AND QUINOLONE INHIBITORS, AND DOMAIN.
RX   PubMed=17132624; DOI=10.1074/jbc.M608183200;
RA   Schubert C., Schalk-Hihi C., Struble G.T., Ma H.C., Petrounia I.P.,
RA   Brandt B., Deckman I.C., Patch R.J., Player M.R., Spurlino J.C.,
RA   Springer B.A.;
RT   "Crystal structure of the tyrosine kinase domain of colony-stimulating
RT   factor-1 receptor (cFMS) in complex with two inhibitors.";
RL   J. Biol. Chem. 282:4094-4101(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 543-918 IN AUTOINHIBITED
RP   CONFORMATION, AND DOMAIN.
RX   PubMed=17292918; DOI=10.1016/j.jmb.2007.01.036;
RA   Walter M., Lucet I.S., Patel O., Broughton S.E., Bamert R.,
RA   Williams N.K., Fantino E., Wilks A.F., Rossjohn J.;
RT   "The 2.7 A crystal structure of the autoinhibited human c-Fms kinase
RT   domain.";
RL   J. Mol. Biol. 367:839-847(2007).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.02 ANGSTROMS) OF 538-922 IN COMPLEX WITH
RP   PYRIMIDINOPYRIDONE INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=18342505; DOI=10.1016/j.bmcl.2008.02.070;
RA   Huang H., Hutta D.A., Hu H., DesJarlais R.L., Schubert C.,
RA   Petrounia I.P., Chaikin M.A., Manthey C.L., Player M.R.;
RT   "Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-
RT   inflammatory FMS inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:2355-2361(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 538-922 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AND FUNCTION IN INFLAMMATION AND
RP   DISEASE.
RX   PubMed=19193011; DOI=10.1021/jm801406h;
RA   Huang H., Hutta D.A., Rinker J.M., Hu H., Parsons W.H., Schubert C.,
RA   DesJarlais R.L., Crysler C.S., Chaikin M.A., Donatelli R.R., Chen Y.,
RA   Cheng D., Zhou Z., Yurkow E., Manthey C.L., Player M.R.;
RT   "Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory
RT   macrophage colony-stimulating factor-1 receptor inhibitors.";
RL   J. Med. Chem. 52:1081-1099(2009).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 538-922 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=20137931; DOI=10.1016/j.bmcl.2010.01.078;
RA   Meyers M.J., Pelc M., Kamtekar S., Day J., Poda G.I., Hall M.K.,
RA   Michener M.L., Reitz B.A., Mathis K.J., Pierce B.S., Parikh M.D.,
RA   Mischke D.A., Long S.A., Parlow J.J., Anderson D.R., Thorarensen A.;
RT   "Structure-based drug design enables conversion of a DFG-in binding
RT   CSF-1R kinase inhibitor to a DFG-out binding mode.";
RL   Bioorg. Med. Chem. Lett. 20:1543-1547(2010).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-32; ARG-362; SER-413; VAL-536;
RP   HIS-693; ASP-920 AND GLN-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS HDLS 774-CYS--ASN-814 DEL; 585-GLY--LYS-619 DELINS ALA;
RP   GLU-589; LYS-633; THR-766; PRO-770; ASN-775; THR-794; TYR-837;
RP   SER-849; PHE-849 DEL; PRO-868; THR-875 AND THR-878, VARIANTS HIS-710;
RP   ARG-747 AND ASP-920, AND CHARACTERIZATION OF VARIANTS HDLS LYS-633;
RP   THR-766 AND THR-875.
RX   PubMed=22197934; DOI=10.1038/ng.1027;
RA   Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N.,
RA   Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M.,
RA   Adamson J., Kouri N., Sundal C., Shuster E.A., Aasly J., MacKenzie J.,
RA   Roeber S., Kretzschmar H.A., Boeve B.F., Knopman D.S., Petersen R.C.,
RA   Cairns N.J., Ghetti B., Spina S., Garbern J., Tselis A.C., Uitti R.,
RA   Das P., Van Gerpen J.A., Meschia J.F., Levy S., Broderick D.F.,
RA   Graff-Radford N., Ross O.A., Miller B.B., Swerdlow R.H., Dickson D.W.,
RA   Wszolek Z.K.;
RT   "Mutations in the colony stimulating factor 1 receptor (CSF1R) gene
RT   cause hereditary diffuse leukoencephalopathy with spheroids.";
RL   Nat. Genet. 44:200-205(2012).
RN   [43]
RP   VARIANTS HDLS ARG-653; PHE-843 AND THR-906.
RX   PubMed=24532199; DOI=10.1007/s00415-014-7257-3;
RA   Battisti C., Di Donato I., Bianchi S., Monti L., Formichi P., Rufa A.,
RA   Taglia I., Cerase A., Dotti M.T., Federico A.;
RT   "Hereditary diffuse leukoencephalopathy with axonal spheroids: three
RT   patients with stroke-like presentation carrying new mutations in the
RT   CSF1R gene.";
RL   J. Neurol. 261:768-772(2014).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for CSF1 and IL34 and plays an essential role in the
CC       regulation of survival, proliferation and differentiation of
CC       hematopoietic precursor cells, especially mononuclear phagocytes,
CC       such as macrophages and monocytes. Promotes the release of
CC       proinflammatory chemokines in response to IL34 and CSF1, and
CC       thereby plays an important role in innate immunity and in
CC       inflammatory processes. Plays an important role in the regulation
CC       of osteoclast proliferation and differentiation, the regulation of
CC       bone resorption, and is required for normal bone and tooth
CC       development. Required for normal male and female fertility, and
CC       for normal development of milk ducts and acinar structures in the
CC       mammary gland during pregnancy. Promotes reorganization of the
CC       actin cytoskeleton, regulates formation of membrane ruffles, cell
CC       adhesion and cell migration, and promotes cancer cell invasion.
CC       Activates several signaling pathways in response to ligand
CC       binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL.
CC       Activation of PLCG2 leads to the production of the cellular
CC       signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate, that then lead to the activation of protein kinase
CC       C family members, especially PRKCD. Phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase, leads to
CC       activation of the AKT1 signaling pathway. Activated CSF1R also
CC       mediates activation of the MAP kinases MAPK1/ERK2 and/or
CC       MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1.
CC       Activated CSF1R transmits signals both via proteins that directly
CC       interact with phosphorylated tyrosine residues in its
CC       intracellular domain, or via adapter proteins, such as GRB2.
CC       Promotes activation of STAT family members STAT3, STAT5A and/or
CC       STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-
CC       1. Receptor signaling is down-regulated by protein phosphatases,
CC       such as INPP5D/SHIP-1, that dephosphorylate the receptor and its
CC       downstream effectors, and by rapid internalization of the
CC       activated receptor. {ECO:0000269|PubMed:12882960,
CC       ECO:0000269|PubMed:15117969, ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16337366, ECO:0000269|PubMed:16648572,
CC       ECO:0000269|PubMed:17121910, ECO:0000269|PubMed:18467591,
CC       ECO:0000269|PubMed:18814279, ECO:0000269|PubMed:19193011,
CC       ECO:0000269|PubMed:19934330, ECO:0000269|PubMed:20489731,
CC       ECO:0000269|PubMed:20504948, ECO:0000269|PubMed:20829061,
CC       ECO:0000269|PubMed:7683918}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16648572, ECO:0000269|PubMed:17121910,
CC       ECO:0000269|PubMed:18342505, ECO:0000269|PubMed:19193011,
CC       ECO:0000269|PubMed:20137931}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. CSF1 or IL34 binding leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib/STI-571 (Gleevec), dasatinib,
CC       sunitinib/SU11248, lestaurtinib/CEP-701, midostaurin/PKC-412,
CC       Ki20227, linifanib/ABT-869, Axitinib/AG013736, sorafenib/BAY 43-
CC       9006 and GW2580. {ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16648572, ECO:0000269|PubMed:17121910,
CC       ECO:0000269|PubMed:18814279, ECO:0000269|PubMed:20137931,
CC       ECO:0000269|PubMed:20156689, ECO:0000269|PubMed:20489731}.
CC   -!- SUBUNIT: Interacts with INPPL1/SHIP2 and THOC5 (By similarity).
CC       Monomer. Homodimer. Interacts with CSF1 and IL34. Interaction with
CC       dimeric CSF1 or IL34 leads to receptor homodimerization. Interacts
CC       (tyrosine phosphorylated) with PLCG2 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with PIK3R1 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with FYN, YES1 and SRC (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CBL, GRB2 and SLA2.
CC       {ECO:0000250, ECO:0000269|PubMed:18342505,
CC       ECO:0000269|PubMed:19193011, ECO:0000269|PubMed:20489731,
CC       ECO:0000269|PubMed:7681396}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07333-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07333-2; Sequence=VSP_047757, VSP_047758;
CC   -!- TISSUE SPECIFICITY: Expressed in bone marrow and in differentiated
CC       blood mononuclear cells.
CC   -!- INDUCTION: Up-regulated by glucocorticoids.
CC       {ECO:0000269|PubMed:7845678}.
CC   -!- DOMAIN: The juxtamembrane domain functions as autoinhibitory
CC       region. Phosphorylation of tyrosine residues in this region leads
CC       to a conformation change and activation of the kinase.
CC   -!- DOMAIN: The activation loop plays an important role in the
CC       regulation of kinase activity. Phosphorylation of tyrosine
CC       residues in this region leads to a conformation change and
CC       activation of the kinase.
CC   -!- PTM: Autophosphorylated in response to CSF1 or IL34 binding.
CC       Phosphorylation at Tyr-561 is important for normal down-regulation
CC       of signaling by ubiquitination, internalization and degradation.
CC       Phosphorylation at Tyr-561 and Tyr-809 is important for
CC       interaction with SRC family members, including FYN, YES1 and SRC,
CC       and for subsequent activation of these protein kinases.
CC       Phosphorylation at Tyr-699 and Tyr-923 is important for
CC       interaction with GRB2. Phosphorylation at Tyr-723 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-708 is important
CC       for normal receptor degradation. Phosphorylation at Tyr-723 and
CC       Tyr-809 is important for interaction with PLCG2. Phosphorylation
CC       at Tyr-969 is important for interaction with CBL.
CC       Dephosphorylation by PTPN2 negatively regulates downstream
CC       signaling and macrophage differentiation.
CC       {ECO:0000269|PubMed:16170366, ECO:0000269|PubMed:20489731}.
CC   -!- PTM: Ubiquitinated. Becomes rapidly polyubiquitinated after
CC       autophosphorylation, leading to its degradation.
CC       {ECO:0000269|PubMed:16170366}.
CC   -!- DISEASE: Note=Aberrant expression of CSF1 or CSF1R can promote
CC       cancer cell proliferation, invasion and formation of metastases.
CC       Overexpression of CSF1 or CSF1R is observed in a significant
CC       percentage of breast, ovarian, prostate, and endometrial cancers.
CC   -!- DISEASE: Note=Aberrant expression of CSF1 or CSF1R may play a role
CC       in inflammatory diseases, such as rheumatoid arthritis,
CC       glomerulonephritis, atherosclerosis, and allograft rejection.
CC   -!- DISEASE: Leukoencephalopathy, diffuse hereditary, with spheroids
CC       (HDLS) [MIM:221820]: An autosomal dominant adult-onset rapidly
CC       progressive neurodegenerative disorder characterized by variable
CC       behavioral, cognitive, and motor changes. Patients often die of
CC       dementia within 6 years of onset. Brain imaging shows patchy
CC       abnormalities in the cerebral white matter, predominantly
CC       affecting the frontal and parietal lobes.
CC       {ECO:0000269|PubMed:22197934, ECO:0000269|PubMed:24532199}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CSF1RID40161ch5q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03663; CAA27300.1; -; mRNA.
DR   EMBL; U63963; AAB51696.1; -; Genomic_DNA.
DR   EMBL; M25786; AAA58421.1; -; mRNA.
DR   EMBL; EU826593; ACF47629.1; -; mRNA.
DR   EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61749.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61750.1; -; Genomic_DNA.
DR   EMBL; BC047521; AAH47521.1; -; mRNA.
DR   EMBL; M14002; AAA35849.1; -; Genomic_DNA.
DR   EMBL; U78096; AAB51235.1; -; Genomic_DNA.
DR   EMBL; M11067; AAA35848.1; -; Genomic_DNA.
DR   EMBL; M14193; AAA35834.1; -; mRNA.
DR   CCDS; CCDS4302.1; -. [P07333-1]
DR   PIR; S08123; TVHUMD.
DR   RefSeq; NP_001275634.1; NM_001288705.2. [P07333-1]
DR   RefSeq; NP_005202.2; NM_005211.3. [P07333-1]
DR   UniGene; Hs.586219; -.
DR   PDB; 2I0V; X-ray; 2.80 A; A=538-678, A=753-922.
DR   PDB; 2I0Y; X-ray; 1.90 A; A=538-678, A=753-922.
DR   PDB; 2I1M; X-ray; 1.80 A; A=538-678, A=753-922.
DR   PDB; 2OGV; X-ray; 2.70 A; A=543-918.
DR   PDB; 3BEA; X-ray; 2.02 A; A=538-678, A=753-922.
DR   PDB; 3DPK; X-ray; 1.95 A; A=538-678, A=771-922.
DR   PDB; 3KRJ; X-ray; 2.10 A; A=538-678, A=753-922.
DR   PDB; 3KRL; X-ray; 2.40 A; A=538-678, A=753-922.
DR   PDB; 3LCD; X-ray; 2.50 A; A=538-919.
DR   PDB; 3LCO; X-ray; 3.40 A; A=550-919.
DR   PDB; 4DKD; X-ray; 3.00 A; C=20-299.
DR   PDB; 4HW7; X-ray; 2.90 A; A=542-919.
DR   PDB; 4LIQ; X-ray; 2.60 A; E=2-512.
DR   PDB; 4R7H; X-ray; 2.80 A; A=542-919.
DR   PDB; 4R7I; X-ray; 2.75 A; A=542-919.
DR   PDB; 4WRL; X-ray; 2.80 A; A/C=20-296.
DR   PDB; 4WRM; X-ray; 6.85 A; A=20-504.
DR   PDBsum; 2I0V; -.
DR   PDBsum; 2I0Y; -.
DR   PDBsum; 2I1M; -.
DR   PDBsum; 2OGV; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3KRJ; -.
DR   PDBsum; 3KRL; -.
DR   PDBsum; 3LCD; -.
DR   PDBsum; 3LCO; -.
DR   PDBsum; 4DKD; -.
DR   PDBsum; 4HW7; -.
DR   PDBsum; 4LIQ; -.
DR   PDBsum; 4R7H; -.
DR   PDBsum; 4R7I; -.
DR   PDBsum; 4WRL; -.
DR   PDBsum; 4WRM; -.
DR   ProteinModelPortal; P07333; -.
DR   SMR; P07333; -.
DR   BioGrid; 107823; 18.
DR   DIP; DIP-59421N; -.
DR   IntAct; P07333; 12.
DR   MINT; MINT-8019993; -.
DR   STRING; 9606.ENSP00000286301; -.
DR   BindingDB; P07333; -.
DR   ChEMBL; CHEMBL1844; -.
DR   DrugBank; DB07167; 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE.
DR   DrugBank; DB07202; 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB06080; ABT-869.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1806; -.
DR   iPTMnet; P07333; -.
DR   PhosphoSitePlus; P07333; -.
DR   BioMuta; CSF1R; -.
DR   DMDM; 547770; -.
DR   PaxDb; P07333; -.
DR   PeptideAtlas; P07333; -.
DR   PRIDE; P07333; -.
DR   DNASU; 1436; -.
DR   Ensembl; ENST00000286301; ENSP00000286301; ENSG00000182578. [P07333-1]
DR   Ensembl; ENST00000543093; ENSP00000445282; ENSG00000182578. [P07333-2]
DR   GeneID; 1436; -.
DR   KEGG; hsa:1436; -.
DR   UCSC; uc003lrm.3; human. [P07333-1]
DR   CTD; 1436; -.
DR   DisGeNET; 1436; -.
DR   GeneCards; CSF1R; -.
DR   GeneReviews; CSF1R; -.
DR   HGNC; HGNC:2433; CSF1R.
DR   HPA; CAB008970; -.
DR   HPA; HPA012323; -.
DR   MalaCards; CSF1R; -.
DR   MIM; 164770; gene.
DR   MIM; 221820; phenotype.
DR   neXtProt; NX_P07333; -.
DR   OpenTargets; ENSG00000182578; -.
DR   Orphanet; 313808; Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia.
DR   PharmGKB; PA26936; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112008; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P07333; -.
DR   KO; K05090; -.
DR   OMA; WKIIESY; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P07333; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-449147; Signaling by Interleukins.
DR   SignaLink; P07333; -.
DR   SIGNOR; P07333; -.
DR   ChiTaRS; CSF1R; human.
DR   EvolutionaryTrace; P07333; -.
DR   GeneWiki; Colony_stimulating_factor_1_receptor; -.
DR   GenomeRNAi; 1436; -.
DR   PRO; PR:P07333; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000182578; -.
DR   CleanEx; HS_CSF1R; -.
DR   ExpressionAtlas; P07333; baseline and differential.
DR   Genevisible; P07333; HS.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:1990682; C:CSF1-CSF1R complex; ISS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IMP:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0036006; P:cellular response to macrophage colony-stimulating factor stimulus; IMP:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0021879; P:forebrain neuron differentiation; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0038145; P:macrophage colony-stimulating factor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0030225; P:macrophage differentiation; TAS:UniProtKB.
DR   GO; GO:0060603; P:mammary gland duct morphogenesis; TAS:UniProtKB.
DR   GO; GO:0030224; P:monocyte differentiation; TAS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0021772; P:olfactory bulb development; IEA:Ensembl.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000147; P:positive regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0031529; P:ruffle organization; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR030658; CSF-1_receptor.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF410; PTHR24416:SF410; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500947; CSF-1_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 5.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 5.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Immunity; Immunoglobulin domain; Inflammatory response;
KW   Innate immunity; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    972       Macrophage colony-stimulating factor 1
FT                                receptor.
FT                                /FTId=PRO_0000016765.
FT   TOPO_DOM     20    517       Extracellular. {ECO:0000255}.
FT   TRANSMEM    518    538       Helical. {ECO:0000255}.
FT   TOPO_DOM    539    972       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       21    104       Ig-like C2-type 1.
FT   DOMAIN      107    197       Ig-like C2-type 2.
FT   DOMAIN      203    290       Ig-like C2-type 3.
FT   DOMAIN      299    399       Ig-like C2-type 4.
FT   DOMAIN      402    502       Ig-like C2-type 5.
FT   DOMAIN      582    910       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     588    596       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      542    574       Regulatory juxtamembrane domain.
FT   REGION      796    818       Activation loop.
FT   ACT_SITE    778    778       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     616    616       ATP. {ECO:0000305}.
FT   MOD_RES     546    546       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     561    561       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     699    699       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:20489731}.
FT   MOD_RES     708    708       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     713    713       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     723    723       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     809    809       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     923    923       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     969    969       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    153    153       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    240    240       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    275    275       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    302    302       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    412    412       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    428    428       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    480    480       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     42     84       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    127    177       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    224    278       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    419    485       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     297    306       ESAYLNLSSE -> GTPSPSLCPA (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_047757.
FT   VAR_SEQ     307    972       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_047758.
FT   VARIANT      32     32       V -> G (in dbSNP:rs56048668).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042038.
FT   VARIANT     245    245       A -> S (in dbSNP:rs41338945).
FT                                /FTId=VAR_061290.
FT   VARIANT     279    279       V -> M (in dbSNP:rs3829986).
FT                                /FTId=VAR_049718.
FT   VARIANT     362    362       H -> R (in dbSNP:rs10079250).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042039.
FT   VARIANT     413    413       G -> S (in dbSNP:rs34951517).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042040.
FT   VARIANT     536    536       L -> V (in dbSNP:rs55942044).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042041.
FT   VARIANT     585    619       GKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLK -> A
FT                                (in HDLS). {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067396.
FT   VARIANT     589    589       G -> E (in HDLS; dbSNP:rs281860268).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067397.
FT   VARIANT     633    633       E -> K (in HDLS; impairs
FT                                autophosphorylation upon stimulation with
FT                                CSF1; dbSNP:rs281860269).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067398.
FT   VARIANT     653    653       C -> R (in HDLS; dbSNP:rs690016559).
FT                                {ECO:0000269|PubMed:24532199}.
FT                                /FTId=VAR_072081.
FT   VARIANT     693    693       P -> H (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042042.
FT   VARIANT     710    710       R -> H (in dbSNP:rs201569135).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067399.
FT   VARIANT     747    747       G -> R (in dbSNP:rs41355444).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067400.
FT   VARIANT     766    766       M -> T (in HDLS; impairs
FT                                autophosphorylation upon stimulation with
FT                                CSF1; dbSNP:rs281860270).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067401.
FT   VARIANT     770    770       A -> P (in HDLS; dbSNP:rs281860271).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067402.
FT   VARIANT     774    814       Missing (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067403.
FT   VARIANT     775    775       I -> N (in HDLS; impairs
FT                                autophosphorylation upon stimulation with
FT                                CSF1; dbSNP:rs281860273).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067404.
FT   VARIANT     794    794       I -> T (in HDLS; dbSNP:rs281860274).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067405.
FT   VARIANT     837    837       D -> Y (in HDLS; dbSNP:rs387906662).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067406.
FT   VARIANT     843    843       I -> F (in HDLS; dbSNP:rs690016558).
FT                                {ECO:0000269|PubMed:24532199}.
FT                                /FTId=VAR_072082.
FT   VARIANT     849    849       F -> S (in HDLS; dbSNP:rs281860277).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067407.
FT   VARIANT     849    849       Missing (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067408.
FT   VARIANT     868    868       L -> P (in HDLS; dbSNP:rs281860278).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067409.
FT   VARIANT     875    875       M -> T (in HDLS; dbSNP:rs281860279).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067410.
FT   VARIANT     878    878       P -> T (in HDLS; dbSNP:rs281860280).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067411.
FT   VARIANT     906    906       I -> T (in HDLS; dbSNP:rs690016560).
FT                                {ECO:0000269|PubMed:24532199}.
FT                                /FTId=VAR_072083.
FT   VARIANT     920    920       E -> D (in dbSNP:rs34030164).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_042043.
FT   VARIANT     921    921       R -> Q (in dbSNP:rs56059682).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042044.
FT   VARIANT     969    969       Y -> C (in dbSNP:rs1801271).
FT                                /FTId=VAR_011953.
FT   MUTAGEN     301    301       L->S: Constitutive kinase activity.
FT                                {ECO:0000269|PubMed:15117969}.
FT   MUTAGEN     708    708       Y->F: Impairs degradation of activated
FT                                CSF1R. {ECO:0000269|PubMed:10340379}.
FT   MUTAGEN     802    802       D->V: Constitutive kinase activity. Loss
FT                                of inhibition by imatinib.
FT                                {ECO:0000269|PubMed:10340379,
FT                                ECO:0000269|PubMed:16170366}.
FT   MUTAGEN     809    809       Y->F: Reduced kinase activity. Reduced
FT                                interaction with SRC, FYN and YES1.
FT                                {ECO:0000269|PubMed:7681396}.
FT   MUTAGEN     969    969       Y->F: Abolishes down-regulation of
FT                                activated CSF1R.
FT                                {ECO:0000269|PubMed:15117969}.
FT   CONFLICT     54     54       P -> A (in Ref. 2; CAA27300).
FT                                {ECO:0000305}.
FT   CONFLICT    247    247       P -> H (in Ref. 7; AAH47521).
FT                                {ECO:0000305}.
FT   CONFLICT    354    354       A -> V (in Ref. 7; AAH47521).
FT                                {ECO:0000305}.
FT   CONFLICT    629    629       A -> S (in Ref. 7; AAH47521).
FT                                {ECO:0000305}.
FT   STRAND       22     25       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       27     32       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       38     43       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       49     51       {ECO:0000244|PDB:4LIQ}.
FT   TURN         55     57       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       58     62       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       64     73       {ECO:0000244|PDB:4LIQ}.
FT   HELIX        76     78       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       80     85       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       95    101       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      108    111       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      113    118       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      123    125       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      127    130       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       132    137       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      139    142       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       143    145       {ECO:0000244|PDB:4WRL}.
FT   STRAND      154    157       {ECO:0000244|PDB:4LIQ}.
FT   TURN        158    160       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      161    166       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       169    171       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      173    181       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      184    187       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      191    196       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      204    208       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      210    215       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      216    218       {ECO:0000244|PDB:4DKD}.
FT   STRAND      220    231       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      234    239       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      248    252       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      257    267       {ECO:0000244|PDB:4LIQ}.
FT   TURN        270    272       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      274    282       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      285    298       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      300    304       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      309    314       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      319    329       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      332    338       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      340    342       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      351    354       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      361    368       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       373    375       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      377    385       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      388    411       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      414    425       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      428    437       {ECO:0000244|PDB:4LIQ}.
FT   TURN        443    445       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      446    454       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      456    459       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      466    473       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      479    488       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      493    498       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      551    553       {ECO:0000244|PDB:4R7H}.
FT   STRAND      556    560       {ECO:0000244|PDB:3BEA}.
FT   HELIX       566    568       {ECO:0000244|PDB:3KRJ}.
FT   HELIX       573    575       {ECO:0000244|PDB:2I1M}.
FT   STRAND      581    590       {ECO:0000244|PDB:2I1M}.
FT   STRAND      592    601       {ECO:0000244|PDB:2I1M}.
FT   STRAND      605    607       {ECO:0000244|PDB:2I1M}.
FT   STRAND      612    618       {ECO:0000244|PDB:2I1M}.
FT   HELIX       624    640       {ECO:0000244|PDB:2I1M}.
FT   STRAND      649    653       {ECO:0000244|PDB:2I1M}.
FT   STRAND      655    658       {ECO:0000244|PDB:2I1M}.
FT   STRAND      660    664       {ECO:0000244|PDB:2I1M}.
FT   HELIX       671    678       {ECO:0000244|PDB:2I1M}.
FT   TURN        684    686       {ECO:0000244|PDB:4R7I}.
FT   TURN        742    744       {ECO:0000244|PDB:2OGV}.
FT   HELIX       753    771       {ECO:0000244|PDB:2I1M}.
FT   HELIX       781    783       {ECO:0000244|PDB:2I1M}.
FT   STRAND      785    787       {ECO:0000244|PDB:2I1M}.
FT   HELIX       788    790       {ECO:0000244|PDB:2I1M}.
FT   STRAND      791    794       {ECO:0000244|PDB:2I1M}.
FT   HELIX       798    800       {ECO:0000244|PDB:2I1M}.
FT   HELIX       803    805       {ECO:0000244|PDB:2I1M}.
FT   TURN        806    808       {ECO:0000244|PDB:3LCO}.
FT   STRAND      809    811       {ECO:0000244|PDB:2I1M}.
FT   STRAND      815    817       {ECO:0000244|PDB:3BEA}.
FT   HELIX       819    821       {ECO:0000244|PDB:2I1M}.
FT   HELIX       824    829       {ECO:0000244|PDB:2I1M}.
FT   HELIX       834    848       {ECO:0000244|PDB:2I1M}.
FT   TURN        849    851       {ECO:0000244|PDB:2I1M}.
FT   HELIX       863    871       {ECO:0000244|PDB:2I1M}.
FT   HELIX       883    892       {ECO:0000244|PDB:2I1M}.
FT   HELIX       897    899       {ECO:0000244|PDB:2I1M}.
FT   HELIX       903    920       {ECO:0000244|PDB:2I1M}.
SQ   SEQUENCE   972 AA;  107984 MW;  A8D99BE237573FE8 CRC64;
     MGPGVLLLLL VATAWHGQGI PVIEPSVPEL VVKPGATVTL RCVGNGSVEW DGPPSPHWTL
     YSDGSSSILS TNNATFQNTG TYRCTEPGDP LGGSAAIHLY VKDPARPWNV LAQEVVVFED
     QDALLPCLLT DPVLEAGVSL VRVRGRPLMR HTNYSFSPWH GFTIHRAKFI QSQDYQCSAL
     MGGRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASSVD VNFDVFLQHN
     NTKLAIPQQS DFHNNRYQKV LTLNLDQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY
     LNLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK LANATTKDTY
     RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY PPEVSVIWTF INGSGTLLCA
     ASGYPQPNVT WLQCSGHTDR CDEAQVLQVW DDPYPEVLSQ EPFHKVTVQS LLTVETLEHN
     QTYECRAHNS VGSGSWAFIP ISAGAHTHPP DEFLFTPVVV ACMSIMALLL LLLLLLLYKY
     KQKPKYQVRW KIIESYEGNS YTFIDPTQLP YNEKWEFPRN NLQFGKTLGA GAFGKVVEAT
     AFGLGKEDAV LKVAVKMLKS TAHADEKEAL MSELKIMSHL GQHENIVNLL GACTHGGPVL
     VITEYCCYGD LLNFLRRKAE AMLGPSLSPG QDPEGGVDYK NIHLEKKYVR RDSGFSSQGV
     DTYVEMRPVS TSSNDSFSEQ DLDKEDGRPL ELRDLLHFSS QVAQGMAFLA SKNCIHRDVA
     ARNVLLTNGH VAKIGDFGLA RDIMNDSNYI VKGNARLPVK WMAPESIFDC VYTVQSDVWS
     YGILLWEIFS LGLNPYPGIL VNSKFYKLVK DGYQMAQPAF APKNIYSIMQ ACWALEPTHR
     PTFQQICSFL QEQAQEDRRE RDYTNLPSSS RSGGSGSSSS ELEEESSSEH LTCCEQGDIA
     QPLLQPNNYQ FC
//
